Free Trial
NASDAQ:IRD

Opus Genetics 3/31/2025 Earnings Report

Opus Genetics logo
$1.21 +0.01 (+0.83%)
Closing price 04:00 PM Eastern
Extended Trading
$1.20 -0.01 (-0.83%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Opus Genetics EPS Results

Actual EPS
-$1.27
Consensus EPS
-$0.34
Beat/Miss
Missed by -$0.93
One Year Ago EPS
N/A

Opus Genetics Revenue Results

Actual Revenue
$3.40 million
Expected Revenue
$11.10 million
Beat/Miss
Missed by -$7.70 million
YoY Revenue Growth
N/A

Opus Genetics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Opus Genetics' next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Opus Genetics Earnings Headlines

Trump’s Endgame? (R.I.P. China)
Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trillion U.S. manufacturing boom. Dubbed Trump’s “New Golden Age” tech, this breakthrough has drawn praise from Elon Musk and NVIDIA’s CEO—and early investors may have a rare chance to get in ahead of the crowd.
See More Opus Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email.

About Opus Genetics

Opus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

View Opus Genetics Profile

More Earnings Resources from MarketBeat